Download opinion
Add to my selection
Quote this publication Print

VIPIDIA (alogliptin), antidiabetic

DIABETOLOGY - New medicinal product
Opinions on drugs - Posted on Feb 23 2015

Reason for request

inclusion

No clinical benefit demonstrated in the management of patients with type 2 diabetes

 

  • VIPIDIA has Marketing Authorisation in the treatment of type 2 diabetes in combination with other blood glucose-lowering medicines, including insulin, when these, combined with diet and exercise, do not provide adequate glycaemic control.
  • Its efficacy has been demonstrated in patients inadequately controlled in dual therapy with metformin or a sulfonylurea and in triple therapy with insulin and metformin.

Clinical Benefit
Substantial

the actual benefit of VIPIDIA is:

  • substantial as dual therapy in combination with metformin,
  • substantial as dual therapy in combination with a sulfonylurea,

 
Moderate

the actual benefit of VIPIDIA is:

moderate as triple therapy in combination with metformin and insulin.
Insufficient

the actual benefit of VIPIDIA is:

  • insufficient as dual therapy in combination with insulin,
  • insufficient as triple therapy in combination with metformin and a sulfonylurea,

Clinical Added Value
no clinical added value

-
Not applicable

Therapeutic use

-

-

Documents

English version

All our publications